Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Choose a wallet that supports both BTC and ETH to manage multiple networks through a single interface, with strong security and broad device compatibility.
28,655 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Palantir just beat earnings, yet its stock fell in after-hours trading as traders priced in slower growth and macro h...
A pivotal moment in monetary policy unfolds as Warsh is confirmed to lead the Fed, with investors weighing how his st...
Anthropic confirms a high-profile hire from Tesla's AI team, expanding its competitive edge in the AI race. The move ...
Public trading disclosures show a sharp spike in activity by the former president, with Trump’s trading volume just s...
A trio of monthly-paying funds could steady-cash a $100,000 portfolio to about $750 a month, aiming for $9,000 in ann...
As tensions flare, shipping traffic through Hormuz is increasingly split between a U.S.-led lane and Iran’s control, ...
A handful of the nation’s most fervent sports markets chose not to bid for hosting World Cup games in 2026, citing fi...
The Global X AI & Technology ETF (AIQ) delivered a six-month surge that helped some investors turn $10,000 into $13,4...
Mexico City's metro facelift for the World Cup has critics accusing officials of prioritizing aesthetics over essenti...
SpaceX's post-IPO moves could ripple through the market. This guide explains what to watch, how to react, and smart s...
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...